It is difficult to assess changes in the function of small airways using conventional measures of pulmonary function since these measurements are relatively insensitive, variable and/or physiologically non-specific. Recent advances in high-resolution computed tomography (HRCT) imaging have made it possible to obtain non-invasive reproducible measurements of structure-function relationships within the lung. This technique has great potential for diagnosing changes in small airway function and in assessing response to drug treatment.
Iritroduction
It is difficult to assess changes in the function of small airways using conventional measures of pulmonary function since these measurements are relatively insensitive, variable and/or physiologically non-specific. Recent advances in high-resolution computed tomography (HRCT) imaging have made it possible to obtain non-invasive reproducible measurements of structure-function relationships within the lung. This technique has great potential for diagnosing changes in small airway function and in assessing response to drug treatment.
This article will outline the role of HRCT in elucidating the effects of HFA-BDP within the small airways. The data presented herein have been adapted from References 1-3.
High-resolution computed tomography to assess small airways function High-resolution computed tomography (HRCT) is a noninvasive imaging technique that can be used to assess pulmonary structure-function relationships (4) (5) (6) . It allows direct radiographic evaluation of luminal calibre and wall thickness of macroscopic airways >2mm in diameter (7), although direct measurement of changes in the calibre of the small airways (<2mm in diameter) is not yet possible. However, HRCT can be used to indirectly assess the small airways by measuring the regional air trapping that results from small airways narrowing and the hyperreactivity of the small airways to methacholine (8.9) . HRCT is also more sensitive than spirometry (8,lO) in providing an accurate and reproducible assessment of small airways changes in mild asthma.
Regional air trapping can be assessed by analysis of lung attenuation curves (LAC) which represent the frequency distribution of lung attenuation units within axial sections in a region of interest; a shift to the left (to lower attenuation) in the LAC at a given standardized lung volume (usually residual volume) reflects an increase in air trapping, whereas a shift to the right (to higher attenuation) Correspondence should be addressed to: Professor Donald P. Tashkin (8) .
Thus, functional HRCT provides reproducible measurements of cross-sectional area of macroscopic airways, as well as regional attenuation characteristics reflecting the patency of peripheral airways. This imaging technique is thought to be more sensitive than pulmonary function tests in the early stages of chronic airways disease and has considerable potential for use in the diagnosis and longitudinal evaluation of patients.
Inhaled corticosteroids and the small airways It is clear that anti-inflammatory treatment needs to be directed to both large and small airways to achieve maximal suppression of inflammation (13) . However, only about 10% of the steroid dose generated from chlorofluorocarbon (CFC)-based metered-dose inhalers reaches the lower respiratory tract with the greater part of the medication being deposited in the large airways (14) .
The most widely used ICS preparations in Europe are beclomethasone dipropionate (BDP), budesonide and fluticasone propionate, with BDP being the first and still the most commonly prescribed ICS. BDP reformulated with the alternative propellant, hydrofluoroalkane (HFA)-134a, results in a solution pFeparation that delivers an aerosol with a much smaller mean particle size (MMAD 0-8-1.2/1m) than that of the suspension aerosols generated by conventional chlorofluorocarbon 1 l/l2 (CFC)-based metered dose inhalers of BDP (MMAD 3.5-4pm). The availability of an extrafine corticosteroid aerosol raises the possibility of more effective delivery of inhaled antiinflammatory medication to the lung periphery in asthmatic patients and thus more effective suppression of inflammation and improved function of the small airways in asthma.
HFA-BDP and the small airways (15) . Lung attenuation was assessed on these parameters for the regions of interest in the right upper and lower lobes at the different measurement times. Automated routines divided axial right lung sections into three area-equivalent gravitational zones: anterior (non-dependent), middle and posterior (dependent), intended to correspond roughly to West's three physiologic zones (16) (Fig. 1) . At any axial level, whole lung as well as regional (gravitational zone) measurements were obtained.
The average median pre-methacholine lung attentuation increased by 39 units in the HFA group between the two visits (indicating less regional air-trapping) but remained essentially unchanged in the CFC group (Table I) .
The average (-I 1 SD) median values of lung attenuation determined from LACs from matched pairs of both pmand post-tne~hacholine images obtained in the mid zone of the region of interest in the right lower lobe at the baseline and post-treatment visits are shown in (Table 2) .
At the baseline visit, the reduction in lung attenuation after methacholine (indicating worsening regional airtrapping in response to methacholine) is similar for the HFA and CFC groups (-29 vs. -26, respectively; P=O*90). In contrast, at the post-treatment visit, the magnitude of the decrease in lung attenuation in response to methacholine is reduced in the HFA group compared to the baseline response in the same subjects (-17 vs. -29), while the magnitude of the decrease in lung attenuation following methacholine compared to the baseline response is augmented in the CFC group. The difference in the effects of the two treatments (HFA vs. CFC) on response to methacholine is statistically significant (P = 0*04), implying a relatively more favourable effect on regional hyperreactivity after treatment with HFA-than with CFC-BDP. Moreover, the lung attenuation response to methacholine improved (i.e. lung attenuation decreased less, implying less increase in regional air-trapping induced by methacholine) significantly more often following treatment with HFA-BDP than CFC-BDP.
In summary, this study demonstrates a greater efficacy of HFA-BDP compared to CFC-BDP in reducing regional air-trapping, as assessed by changes in the regional distribution of lung attenuation. In addition, greater efficacy of HFA-BDP is also shown in reducing regional airways hyperreactivity, as determined by changes in regional air-trapping after bronchoprovocation with -17 12*+ methacholine, again assessed by analysing changes in the distribution of lung attenuation. These differences between the effects of the two formulations of BDP on regional airtrapping and regional hyperreactivity are consistent with the greater penetration of the smaller airways by the extrafine HFA, compared to the larger particle size CFC, corticosteroid aerosol previously demonstrated by radiolabelled aerosol deposition studies (17) .
Conclusion
In conclusion, functional imaging provides a sensitive new tool for assessing the long-term effect of corticosteroid aerosols on small airways function. Using this new assessment tool it has been shown that the extrafine HFA-BDP aerosol appears to have greater efficacy than the same dose of the larger particle size CFC-BDP aerosol on small airways function, most likely due to the more effective delivery of the extrafine corticosteroid aerosol to the lung periphery. Additional studies are needed in larger numbers of patients with asthma of varying severity over longer periods of time to assess further the impact of targeting the small airways for treatment with antiinflammatory agents on lung function and other clinical outcomes.
